Philips and Diagnostics Development win European Union 'Horizon Prize - Better Use of Antibiotics'

PhilipsRoyal Philips (NYSE: PHG, AEX: PHIA), a leader in HealthTech, and Diagnostics Development, a P&M Venge company spin-off from Uppsala University (Sweden), have demonstrated a proof-of-concept for the rapid and reliable detection of bacterial infection. The test is based on Philips' Minicare I-20 handheld diagnostics platform and detects the human neutrophil lipocalin (HNL) biomarker in a single 'finger-prick' drop of blood. In recognition of the test's ability to distinguish between acute bacterial and viral infections, and thereby mitigate the unnecessary use of antibiotics, the two companies were awarded the European Union 'Horizon Prize - Better Use of Antibiotics' during a special award ceremony on the evening of February 6, 2017.

Antimicrobial agents - such as antibiotics - have dramatically reduced the number of deaths from infectious diseases since their introduction 70 years ago. However, through their overuse and misuse, many micro-organisms have become resistant to them. It is estimated that each year this growing antimicrobial resistance (AMR) causes around 25,000 deaths and accounts for over EUR 1.5 billion in healthcare costs and productivity losses in Europe alone, making it one of the greatest challenges facing society today. To boost development and bring new and innovative players to AMR research, the EU issued a prize for the individual or team that most effectively meets the following challenge: "to develop a rapid test that will allow healthcare providers to distinguish at the point of care between patients with upper respiratory tract infections that require antibiotics and those that can be treated safely without antibiotics".

"This prize is a great recognition of how collaboration can lead to innovative diagnostic solutions that improve patient care," said Marcel van Kasteel, CEO of Handheld Diagnostics at Philips. "The HNL program for detection of bacterial infections perfectly fits with our 'open platform' strategy of bringing innovative biomarker content onto the Minicare I-20 platform in order to offer healthcare professionals a panel of relevant tests for acute settings. Activities are ongoing to further develop the HNL test for eventual implementation in routine clinical practice.

"In various studies, HNL has demonstrated superior performance compared to biomarkers currently used to diagnose bacterial infection," said Per Venge, CEO of P&M Venge AB. "I am therefore very excited that we have been able to successfully demonstrate the detection of HNL on the Minicare I-20 using blood samples from patients with upper respiratory tract infections in the Uppsala University hospital, where within a few minutes patients with a bacterial infection could clearly be distinguished from those with viral infections or other conditions."

Based on Philips' proprietary biosensor technology, the Minicare I-20 handheld diagnostics platform is designed to detect multiple target molecules at very low concentrations in a single 'finger-prick' blood sample, and display the results on a handheld analyzer within minutes. Philips already has CE marking for its Minicare I-20 based cardiac troponin I (cTnI) blood test for the rapid point-of-care diagnosis of heart attack, and it is currently developing further tests for acute care settings.

Minicare I-20 is simple and easy to use by non-laboratory staff. The analyzer's built-in connectivity allows direct transfer of the data to laboratory and hospital information systems to update patient files, while integrated calibration and fail-safe functionalities ensure the robustness and accuracy needed for confident on-the-spot decision making.

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. The company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Headquartered in the Netherlands, Philips' health technology portfolio generated 2016 sales of EUR 17.4 billion and employs approximately 71,000 employees with sales and services in more than 100 countries.

Most Popular Now

Interactive Health Apps May Inspire Heal…

Just like real doctors and nurses, online health tools with good - but controlled - communication skills can promote healthier lifestyles, according to researchers. However, if their tone is conversational...

Read more

Augmented Reality Visor to Dramatically …

Employing new photonics technology, European scientists are developing a new Augmented Reality surgical visor in a bid to improve accuracy of interventions, showing anaesthetic and medical data while superimposing a...

Read more

Call for Papers: EHB 2017 - IEEE Interna…

22 - 24 June 2017, Sinaia, Romania. The 6-th edition of the International Conference on e-Health and Bioengineering, EHB 2017, will take place in the city of Sinaia, Romania. This year...

Read more

UK and Italian Health Tech Firms to Help…

Data sharing ambitions set out in newly published sustainability and transformation plans (STPs) have been given a boost by a new strategic partnership between data management specialist Stalis and Italy's...

Read more

From Health Apps to Nursing Robots - A G…

25 - 27 April 2017, Berlin, Germany. Around the world the subject of e-Health is steadily gaining in importance, whether it involves electronic patient files, online video consultations or any of...

Read more

Philips Teams Up with German Startup One…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced a partnership agreement with German digital health company Onelife Health to jointly develop innovative connected health...

Read more

EU eHealth Competition 2017

The eHealth Competition is an initiative that rewards the best eHealth / mHealth solutions produced by European SMEs (Small and Medium Enterprises). Its objective is to support business success of...

Read more

Philips and LabPON Plan to Create World…

Royal Philips (NYSE: PHG, AEX: PHIA) and LabPON, the first clinical laboratory to transition to 100% histopathology digital diagnosis, have announced its plans to create a digital database of massive...

Read more

Startupbootcamp Digital Health Berlin: C…

Startupbootcamp Digital Health Berlin supports innovative startups that combine medical knowledge with smart technologies, with special focus on behavior change, diagnostics and genomics, big data and analytics. Startupbootcamp provides mentorship...

Read more

Virtual Reality Cognitive Training Game …

Greek researchers demonstrated the potential of a self-administered virtual supermarket cognitive training game for remotely detecting mild cognitive impairment (MCI), without the need for an examiner, among a sample of...

Read more

Technology Boost for Health and Social C…

Health and social care organisations aiming to be fully compliant with the government’s Personalised Health and Care 2020 plan, can now access electronic health record (EHR) and healthcare integration technologies...

Read more

Philips Introduces Advanced Radiology So…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has unveiled new advanced radiology solutions at the 2017 European Congress of Radiology (ECR). In response to today's...

Read more
(HEALTH IT) SPACE - Take a look at who has just Joined